Here, Jeffrey Almond discusses the selection of articles in this Focus ... Their ultimate goal is epitope engineering of important vaccine antigens, although the feasibility of this for large ...
Several observations point toward the possibility of a vaccine development strategy ... of most of these surface proteins has made antigen selection problematic. Obstacles to the development ...
Selection of 19 individual researchers among ... Cheever and colleagues establish a definition of 'ideal' antitumor vaccine antigens based on weighted criteria, including: evidence of antitumor ...
The approach builds off the current bivalent Human Hookworm Vaccine now in clinical development and would ultimately add both a larval Ascaris lumbricoides antigen and an adult-stage Trichuris ...
TG4050 is an individualized immunotherapy being developed for solid tumours that is based on Transgene’s myvac platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen ...
AI-Immunology™ can select ERV antigens for precision therapeutic cancer vaccines, offering therapeutic options for multiple specific cancer types and potentially enabling treatment for patients ...